CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Cash flows from operating activities:
Net loss	$ (679,948)	$ (539,102)	$ (348,535)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	21,498	9,826	3,522
Non-cash operating lease costs	35,553	33,475	27,712
Amortization of deferred commissions	37,876	28,841	16,986
Stock-based compensation, net of amounts capitalized	605,095	301,441	78,399
Net amortization (accretion) of premiums (discounts) on investments	48,002	8,630	(5,459)
Net unrealized gains on strategic investments in equity securities	(27,621)	0	0
Other	1,297	4,580	1,476
Changes in operating assets and liabilities, net of effect of business combinations:
Accounts receivable	(251,652)	(116,289)	(116,869)
Deferred commissions	(95,877)	(51,444)	(68,595)
Prepaid expenses and other assets	(159,159)	(62,349)	(10,811)
Accounts payable	7,371	(2,878)	1,116
Accrued expenses and other liabilities	79,772	58,252	34,994
Operating lease liabilities	(38,249)	(31,281)	(13,455)
Deferred revenue	526,221	312,881	222,961
Net cash provided by (used in) operating activities	110,179	(45,417)	(176,558)
Cash flows from investing activities:
Purchases of property and equipment	(16,221)	(35,037)	(18,583)
Capitalized internal-use software development costs	(12,772)	(5,293)	(4,265)
Cash paid for business combinations, net of cash acquired	0	(6,035)	(6,314)
Purchases of intangible assets	(24,334)	(8,374)	0
Purchases of investments	(4,250,338)	(4,859,852)	(622,854)
Sales of investments	440,069	177,070	14,087
Maturities and redemptions of investments	3,842,796	700,876	776,424
Net cash provided by (used in) investing activities	(20,800)	(4,036,645)	138,495
Cash flows from financing activities:
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	0	478,573	24,121
Proceeds from initial public offering and private placements, net of underwriting discounts	0	4,242,284	0
Proceeds from early exercised stock options	0	159	6,213
Proceeds from exercise of stock options	127,036	53,378	27,526
Proceeds from issuance of common stock under employee stock purchase plan	52,227	0	0
Proceeds from repayments of a nonrecourse promissory note	0	2,090	0
Repurchases of early exercised stock options and restricted common stock	0	(30)	(391)
Payments of deferred purchase consideration for business combinations	(1,065)	(1,164)	0
Net cash provided by financing activities	178,198	4,775,290	57,469
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(236)	(11)	0
Net increase in cash, cash equivalents, and restricted cash	267,341	693,217	19,406
Cash, cash equivalents, and restricted cash—beginning of period	835,193	141,976	122,570
Cash, cash equivalents, and restricted cash—end of period	1,102,534	835,193	141,976
Supplemental disclosures of cash flow information:
Cash paid for income taxes	1,482	1,195	1,428
Supplemental disclosures of non-cash investing and financing activities
Property and equipment included in accounts payable and accrued expenses	5,115	6,941	589
Stock-based compensation included in capitalized software development costs	23,620	2,072	1,080
Vesting of early exercised stock options and restricted common stock	750	3,502	5,791
Equity consideration in connection with a business combination	0	0	4,749
Intangible assets included in accrued expenses and other liabilities	4,544	0	0
Net change in unrealized gains or losses on available-for-sale debt securities	15,807	105	200
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	1,085,729	820,177	127,206
Restricted cash—included in other assets and prepaid expenses and other current assets	16,805	15,016	14,770
Total cash, cash equivalents, and restricted cash	$ 1,102,534	$ 835,193	$ 141,976